A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype
Latest Information Update: 28 Apr 2025
At a glance
- Drugs Autoimmune-diabetes-vaccine-(Diamyd)-Diamyd-Medical (Primary) ; Vitamin D
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DIAGNODE-3
- Sponsors Diamyd Medical AB
Most Recent Events
- 21 Apr 2025 According to a Diamyd Medical AB media release, The Company is currently enrolling only patients with the appropriate HLA genotype in its Phase 3 trial DIAGNODE-3 trail and a registrational Phase 3 readout expected within 12 months.
- 12 Feb 2025 According to a Diamyd Medical AB media release, the company will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), in support of the DIAGNODE-3 Phase 3 trial to facilitate the potential submission of a regulatory filing for approval.
- 29 Jan 2025 According to a Diamyd Medical AB media release, Recruitment in DIAGNODE-3, our pivotal Phase-3 study, continues to progress, with over 200 patients (more than needed for the planned early read-out in March-26)